Flexion Therapeutics

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Retrieved on: 
Thursday, February 15, 2024
Quality of life, Regeneron Pharmaceuticals, Anatomical terms of motion, Patient, AbbVie, Therapy, Procter & Gamble, Eye, Flexion Therapeutics, Management

BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer.

Key Points: 
  • BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer.
  • “As we continue our commitment to advancing our drug portfolio in order to enhance the quality of life for patients, I am thrilled to announce the promotion of Steve Meyers to the role of Chief Commercial Officer,” said Antony Mattessich, CEO of Ocular Therapeutix.
  • With his expertise and dedication, I am confident he will play a pivotal role in driving Ocular’s commercial efforts forward.”
    “I am truly honored by this opportunity to serve as Chief Commercial Officer," said Steve Meyers.
  • Prior to joining Ocular, Mr. Meyers served as Vice President of Sales at Flexion Therapeutics in the orthopedic space.

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

Retrieved on: 
Monday, September 18, 2023
Yee, Medical Affairs Bureau, Senior, Harvard T.H. Chan School of Public Health, Intarcia Therapeutics, Biotechnology, AB, Boston, Harvard College, OSA, Harvard University, Harvard Medical School, Genzyme, Public health, AstraZeneca, Vertex Pharmaceuticals, Hospital, MPH, Health administration, Therapy, Obstructive sleep apnea, Flexion Therapeutics, Pharmaceutical industry, MD

Dr. Yee has more than 25 years of leadership experience at leading biotechnology, pharmaceutical, and healthcare technology companies, and at a major academic medical center.

Key Points: 
  • Dr. Yee has more than 25 years of leadership experience at leading biotechnology, pharmaceutical, and healthcare technology companies, and at a major academic medical center.
  • Prior to joining Apnimed, Dr. Yee served as Chief Medical Officer at Sobi North America.
  • Dr. Yee earned an MD from Harvard Medical School, an MPH in Health Care Management from the Harvard T.H.
  • Prior to his career in industry, Dr. Yee held leadership roles at Boston Children’s Hospital and was a faculty member at Harvard Medical School.

Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases

Retrieved on: 
Monday, May 15, 2023
Professional Services, Health, Neurology, Genetics, Venture Capital, Clinical Trials, Biotechnology, Drug development, Cell death, Doctor of Philosophy, Initiative, Nido, DSM-IV codes, SBMA, Flagship Pioneering, Alexion Pharmaceuticals, Lilly, Patient, Anatomical terms of motion, Series, Spinal and bulbar muscular atrophy, Biology, Eli Lilly and Company, Protein, Therapy, ALS, FTD, Flexion Therapeutics, AR, Disease, Pharmaceutical industry, Management

Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, emerged from stealth today backed by an industry leading investor syndicate and having raised a combined $109 million in Seed, Series A and B financings.

Key Points: 
  • Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, emerged from stealth today backed by an industry leading investor syndicate and having raised a combined $109 million in Seed, Series A and B financings.
  • Bioluminescence Ventures led the Series B round with participation from additional new investors and the noted insiders.
  • Nido Bio is leveraging advancements in the understanding of human genetics and disease to develop a sustainable pipeline of novel small molecule medicines to improve the daily lives of patients suffering from neurological diseases.
  • Across its programs, Nido Bio is addressing the fundamental biology of disease to restore healthy cell function.

Cellarity Strengthens Executive Leadership Team

Retrieved on: 
Tuesday, April 11, 2023
Research, Technology, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Upjohn, Georgia Tech, Pharming, Head, McKinsey & Company, Associate, Wharton School of the University of Pennsylvania, Acquisition, Chemical engineering, Indian Institutes of Technology, MMSc, Data science, Software, Corporate development, Business development, University, Therapy, Boston, Forma, Corporation, Drug discovery, Biology, IMPL, Mallinckrodt, Translational medicine, CBO, CFO, Drug development, Doctor of Philosophy, Johnson & Johnson, Harvard Medical School, Shire (pharmaceutical company), Flagship Pioneering, Novartis, Novo Nordisk, Flexion Therapeutics, Management, Pharmaceutical industry, Wine Cellar Innovations

The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.

Key Points: 
  • The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.
  • These new leadership appointments will allow Cellarity to accelerate development of its platform and progress its pipeline programs towards the clinic.
  • “Their appointments are a great complement to the already well experienced senior leadership team which includes Parul Doshi, recently promoted to Chief Data Officer.
  • Prior to joining Cellarity, he was previously Executive Medical Director in Clinical Development at Forma Therapeutics (acquired by Novo Nordisk) where he led their flagship sickle cell disease program.

Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics

Retrieved on: 
Wednesday, March 29, 2023
Picower Institute for Learning and Memory, Bachelor of Science in Human Biology, Operation, Therapy, Senior, Doctor of Philosophy, Pharmacokinetics, Research, MIT, DSM-IV codes, Science, Development, St. Lawrence University, Vanderbilt, MD, Translational research, Patient, Memory, Spectrum, Drug discovery, Toxicology, Growth, Bacteria, IND, Flexion Therapeutics, Massachusetts Institute of Technology, Disease, Pharmaceutical industry, Chemistry, Axial, Pharmacology

WOBURN, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced key promotions in its research and development organization. These promotions recognize the Axial team’s scientific and clinical expertise and support its continued growth to advance the company’s pipeline, including the ongoing Phase 2b clinical trial in autism and preclinical evaluation of a development candidate for Parkinson’s Disease. Preclinical R&D promotions include: Rebecca Senter, PhD, to Vice President, Head of Preclinical Research and Development, Radka Graf, to Director, Preclinical Development and Operations and Chris Oalmann, PhD, to Senior Director, Chemistry. In addition to these promotions, Gabriel Belfort, MD, PhD, who was appointed Vice President, Clinical Development Science and Operations in 2022, also was promoted to Senior Vice President, Clinical Development Science and Operations.

Key Points: 
  • WOBURN, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced key promotions in its research and development organization.
  • These promotions recognize the Axial team’s scientific and clinical expertise and support its continued growth to advance the company’s pipeline, including the ongoing Phase 2b clinical trial in autism and preclinical evaluation of a development candidate for Parkinson’s Disease.
  • Preclinical R&D promotions include: Rebecca Senter, PhD, to Vice President, Head of Preclinical Research and Development, Radka Graf, to Director, Preclinical Development and Operations and Chris Oalmann, PhD, to Senior Director, Chemistry.
  • “The significant advancement of our pipeline of novel microbiome therapeutics has only been possible because of our dedicated and talented team.

Neosoma Expands Its Board of Directors with Debbie Millin and Frederick Driscoll

Retrieved on: 
Wednesday, March 15, 2023
Neurology, Software, Oncology, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Harvard Club of Boston, CCA Global Partners, Software as a service, Therapy, Sale, Trustee, Brain, Accounting, Flexion Therapeutics, Anatomical terms of motion, Chiba Museum of Science and Industry, Physician, Museum, Bentley University, Growth, Financial management, Culture, Harvard Business School, Neuro, Entrepreneurship, Management, Science

Neosoma, Inc. , an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, announces today it has appointed Debbie Millin and Frederick Driscoll to its board of directors.

Key Points: 
  • Neosoma, Inc. , an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, announces today it has appointed Debbie Millin and Frederick Driscoll to its board of directors.
  • “Key to executing on our strategy is ensuring that the company has a diverse and experienced board of directors,” said Ken Kolodziej, Neosoma’s CEO and Co-Founder.
  • Debbie also serves on multiple committees for the Board of Trustees at the Museum of Science in Boston, and the Harvard Club of Boston.
  • Frederick Driscoll is an accomplished healthcare executive with more than 25 years of financial management of life sciences companies.

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

Retrieved on: 
Thursday, January 5, 2023
Bupivacaine, EBITDA, Therapy, Flexion Therapeutics, COVID-19, Acquisition, Growth, 340B Drug Pricing Program, Pharmaceutical industry, Animal, Lithium, Anatomical terms of motion

TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.

Key Points: 
  • TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.
  • ZILRETTA net product sales of $28.0 million and $12.7 million for the fourth quarters of 2022 and 2021, respectively, and $9.4 million and $8.9 million for the months of December 2022 and 2021, respectively.
  • Other revenue, including sales of bupivacaine liposome injectable suspension, royalties and collaborative licensing revenue, was $1.4 million and $1.8 million in the fourth quarters of 2022 and 2021 and $1.4 million and $0.7 million for the months of December 2022 and 2021, respectively.
  • Other revenue, including sales of bupivacaine liposome injectable suspension, royalties and collaborative licensing revenue was $9.1 million in 2022, compared with $6.2 million in 2021.

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

Retrieved on: 
Thursday, October 13, 2022
U.S. Securities and Exchange Commission, Engineering, Disease, SEC, Therapy, Growth, Director, Immunity, Severe acute respiratory syndrome coronavirus 2, Annual report, Antibody, Biotechnology, Research, Flexion Therapeutics, Security (finance), Nasdaq, Technology, Private Securities Litigation Reform Act, Infection, Degenerative disease, Virology, Board, CEO, Intention, Safety, GLOBE, Forward-looking statement, COVID-19, Pharmaceutical industry, Management, Vaccine

Jane Pritchett Henderson, chief financial and business officer, and Eric Kimble, chief commercial officer, are transitioning from the company to pursue other opportunities.

Key Points: 
  • Jane Pritchett Henderson, chief financial and business officer, and Eric Kimble, chief commercial officer, are transitioning from the company to pursue other opportunities.
  • The company has appointed industry veteran Fred Driscoll as interim chief financial officer.
  • Fred has decades of experience in the successful financial leadership of biotechnology companies, including tenures as chief financial officer at companies including Renovacor, Flexion Therapeutics and Novavax.
  • An executive search has been initiated to identify a new chief financial officer as well as a business development executive.

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Retrieved on: 
Monday, August 15, 2022
MDS, FDA, U.S. Securities and Exchange Commission, Brown University, Macrocytic anemia, Sickle cell disease, Private Securities Litigation Reform Act, GLOBE, Pyruvate kinase deficiency, SEC, Leadership, Sale, Harvard University, White House, Patent, Security (finance), Rutgers University, Flexion Therapeutics, Johns Hopkins University, Merck, Marketing, Patient, Therapy, Politics, COVID-19, Doctor of Philosophy, Eagleton Institute of Politics, Management, Wharton School of the University of Pennsylvania, University of North Carolina at Greensboro, Chapel Hill, MIT, Risk, NASDAQ, PK, Biology, Anemia, Biochemistry, ZS, Genetics, Goal, University, Thalassemia, Agios Pharmaceuticals, EMA, Public policy, Georgetown University, Wendell Pritchett, Pharmaceutical industry, Imara, Anatomical terms of motion

Agios is committed to assembling a top-notch, diverse board dedicated to realizing the companys long-term success and creating value for patients, shareholders, our team and all our stakeholders, said Brian Goff, chief executive officer of Agios.

Key Points: 
  • Agios is committed to assembling a top-notch, diverse board dedicated to realizing the companys long-term success and creating value for patients, shareholders, our team and all our stakeholders, said Brian Goff, chief executive officer of Agios.
  • Rahul and Cynthia are seasoned biopharmaceutical executives with critical expertise to help us maximize Agios potential.
  • He has served as Imaras president and chief executive officer and a member of the board of directors since June 2018.
  • Dr. Ballal joined Imara from Northern Biologics, where he served as chief business officer, and Versant Ventures, where he served as an entrepreneur-in-residence.

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Retrieved on: 
Monday, July 18, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Research, Medivation, University, Global, Agenus, Cancer, Patient, Rituximab, Massachusetts Institute of Technology, Osteoarthritis, Flexion Therapeutics, Peking University Health Science Center, NYSE, Indolent lymphoma, New Drug Application, Degenerative disease, Regulatory affairs, NUVB, Nivolumab, Pain management, Medical school, Genzyme, Bristol Myers Squibb, Ipilimumab, Company, NDA, Pharmacovigilance, Biostatistics, Celgene, Data management, Therapy, Prostate cancer, Peking University School of Transnational Law, Quality, Translational research, Pharmaceutical industry, Medical device

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer.
  • I am honored to join Nuvation Bio and oversee the clinical development of innovative therapies for the most difficult-to-treat cancers, said Dr. Liu.
  • Nuvation Bios mission to bring meaningful cancer treatments to patients who have nearly exhausted all options deeply resonates with me, said Ms. Wentworth.
  • Most recently, Dr. Liu served as the Chief Medical Officer at a biotechnology company based in Shanghai, China.